LAGENIO Unveils Next-Gen AI-Powered Kids Smartwatch with Simcard at IFA 2025
9.9.2025 08:07:00 CEST | Business Wire | Press Release
LAGENIO, a global leader in kid’s smartwatches, is set to debut its next-generation innovation at IFA 2025 in Berlin, Germany, Booth NO: H27h-12. LAGENIO has unveiled two new models for Europe market: the K9, a premium AI-powered watch phone, and the K3, a creative entry-level model. Designed as a safe first phone alternative for children ages 4 to 12, both devices combine secure communication and parental controls with features that encourage physical activity and healthy digital habits.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250905079305/en/
LAGENIO kids smartwatches in colorful designs with fun cartoon watch faces, fitness tracking, safety features, and educational functions
“Parents want to give their kids independence without compromising safety, and kids want technology that feels exciting and fun,” said Li Leung, CEO of LAGENIO. “With the new LAGENIO platform, we have combined performance, design, and child-friendly features to deliver a smartwatch that kids love—and parents can feel secure about.”
LAGENIO K9 — The World’s First AI 4G Kids Watch
LAGENIO K9 kid’s smartwatch delivers comprehensive hardware upgrades, including a AMOLED display, a slimmer, stylish design, and a higher-frequency CPU for smooth and responsive performance.
What truly distinguishes the K9 is its AI-powered software based on ChatGPT. A lightweight local AI model provides personalized assistance tailored to each child’s needs, including drawing guidance, question answering, writing support, and storytelling.
With these intelligent capabilities, the K9 redefines the kid’s smartwatch category for the AI era, offering smart, reliable, and interactive experiences that empower kids while giving parents peace of mind.
LAGENIO K3 — Streamlined functions dedicated to children’s safety and connection
The K3 focuses on what matters most: kid’s safety and seamless communication. Equipped with reliable calling, real-time location tracking, and durable kid-friendly design, the K3 offers kids more color options for housing combinations, ensures parents can stay connected with peace of mind while kids enjoy greater creativity.
About LAGENIO
Founded in 2019, LAGENIO is a global leader in 4G kid’s smartwatches. We are committed to creating a world where innovation and care thrive to empower families worldwide. LAGENIO has become a trusted brand for families worldwide. The company serves more than 36 million users across 45 countries.
LAGENIO cares about data security and data privacy. All user data will be saved in local Europe server without transmission to any other country.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250905079305/en/
Contacts
SHENZHEN LAGENIO TECHNOLOGY CO., LIMITED
sales@lagenio.com
Visit: www.lagenio.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.lagenio.com
&esheet=54319565&newsitemid=20250905079305&lan=en-US&anchor=www.lagenio.com&inde
x=1&md5=917f1ca9d0c4705b799b953dad8ae7b0
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom